February 2, 2018 / 11:49 AM / 6 months ago

BRIEF-TG Therapeutics Announces Updated Results From The Ongoing Phase 2 Study Of Ublituximab

Feb 2 (Reuters) - Tg Therapeutics Inc:

* TG THERAPEUTICS, INC. ANNOUNCES UPDATED RESULTS FROM THE ONGOING PHASE 2 STUDY OF UBLITUXIMAB (TG-1101) IN PATIENTS WITH MULTIPLE SCLEROSIS AT THE THIRD ANNUAL ACTRIMS FORUM 2018

* TG THERAPEUTICS INC - TG-1101 WAS WELL TOLERATED ACROSS ALL PATIENTS INCLUDING THOSE RECEIVING 1 HOUR INFUSIONS AT PHASE 3 DOSE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below